FDA approves 6-month HIV prevention shot
Pharmaceutical company Gilead Sciences announced Wednesday the Food and Drug Administration (FDA) has approved its six-month, twice-yearly HIV PrEP injection, which was found in trials to be more than 99.9 percent effective among participants.
Gilead's product Yeztugo, a form of lenacapavir, was approved for reducing the risk of sexually acquired HIV in adults and adolescents when injected twice a year. Lenacapavir is also marketed as Sunlenca, administered orally or through injection, as a treatment for HIV/AIDS in combination with other drugs. The drug is solely manufactured by Gilead.
There are currently three available HIV PrEP options: two oral pills taken daily — Truvada and Descovy — and a long-acting injection called Apretude administered every two months.
'Yeztugo could be the transformative PrEP option we've been waiting for — offering the potential to boost PrEP uptake and persistence and adding a powerful new tool in our mission to end the HIV epidemic,' Carlos del Rio, co-Director of the Emory Center for AIDS Research, said in a statement shared by Gilead.
In a Phase 3, double-blind, randomized study, there were only two HIV infections among 2,179 participants who received Yeztugo subcutaneous injections twice a year.
Lenacapavir is currently not approved for HIV prevention outside of the U.S., though it is approved for treating HIV in several countries.
'In the U.S., Gilead is working closely with insurers, healthcare systems and other payers with the goal of ensuring broad insurance coverage for Yeztugo,' the company said in a statement. 'Additionally, for eligible commercially insured individuals with commercial insurance, Gilead's Advancing Access® Co-Pay Savings Program will reduce out-of-pocket costs to as little as zero dollars.'
Carl Schmid, Executive Director of the HIV+Hepatitis Policy Institute, called the approval a 'monumental advance in HIV prevention.'
'Long-acting PrEP is now not only effective for up to six months but also improves adherence and will reduce HIV infections—if people are aware of it and payers, including private insurers, cover it without cost-sharing as a preventive service,' said Shmid.
'Recent actions by the Trump administration to decimate HIV prevention jeopardize access to preventive measures such as PrEP,' he added.
'In fact, the president's budget zeroes out all CDC HIV prevention and surveillance funding, hampering our nation's ability to make people aware of and access new HIV prevention measures. Dismantling these programs means that there will be a weakened public health infrastructure and much less HIV testing, which is needed before a person can take PrEP.'
The Hill has reached out to the White House for comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Elton John: We've made great progress on HIV/AIDS. Budget cuts threaten to set us back.
Ryan White was a spirited, bright kid who loved basketball, Nintendo and dreaming big. In 1984, 13-year-old Ryan contracted HIV through a contaminated blood transfusion used to treat his hemophilia. With widespread misconceptions about HIV/AIDS dominating the headlines, and fear overruling facts, Ryan was barred from attending his school and driven from his hometown of Kokomo, Indiana. His harrowing story suddenly thrust Ryan onto the national stage, where he transformed the attention into a powerful force for changing perceptions about those living with HIV/AIDS. He had no idea how far his message would reach. Yet he was determined to use it for the greater good. His courage inspired the creation of the Elton John AIDS Foundation, which continues to help people across America, and around the world, stay safe and well. At the time of his diagnosis, doctors gave Ryan only six months to live. On April 8, 1990, six precious years later, we sat together at Ryan's bedside and held his hands as he lost his young, heroic life to AIDS. First lady Barbara Bush attended his funeral, and businessman Donald Trump came to the family home to pay his respects. When Americans needed to take compassionate action, Ryan opened the door and urged everyone to take heart and to help. Four months later, in his name, Congress nearly unanimously enacted the Ryan White CARE Act – providing essential HIV care and treatment to Americans living with the virus. After years of fearmongering and paralysis, the U.S. government had finally committed to join the fight against our common enemy: AIDS. Ryan would be grateful for the progress being made. Today, more than 500,000 Americans living with HIV get lifesaving treatment through the Ryan White CARE Act. Opinion: The CDC won't fund local organizations' HIV prevention, ignoring KY health needs In 2019, President Trump proudly launched the End the HIV Epidemic initiative in his State of the Union address − a focused prevention effort to end the HIV epidemic in America by 2030. This evidence-based strategic initiative has achieved remarkable results, reducing new HIV infections by 21% in targeted communities and connecting people newly diagnosed with HIV to vital care and support services. This push to end AIDS is in full swing across America, but the work is not done yet – with young people, particularly in the South, now most severely impacted. We are grateful that the draft budget before Congress continues critically important funding for the Ryan White CARE Act and the End the HIV Epidemic efforts. That is an affirmation of these programs' effectiveness and bipartisan support. However, the proposal also would end federal funding to states for HIV surveillance, testing and education; for community-based organizations that reach those most at risk; and for substance abuse treatment and mental health programs that are crucial for driving down HIV infections. Attempts to cut Medicaid are also alarming, as more than 40% of people living with HIV have their care and treatment covered by Medicaid. Without this essential insurance, scores of people living with HIV won't get the care and medicines they need to keep them healthy. The president has said don't mess with Medicaid. We agree. Your Turn: What readers told us about Medicaid | Opinion Forum Programs that provide treatment, fuel prevention and fight stigma should be expanded, not eliminated, as we work toward eradicating the disease that ended Ryan's life. The game-changing opportunity of the moment is to scale up prevention medication that keeps people HIV-free. The recent American-led development of PrEP − a pill or shot that prevents the virus from taking hold − is just the tool we need to end AIDS, but only if we make it accessible to those who need it. The economics are compelling: 14,000 people can receive generic PrEP ($30 annually) for the lifetime cost of treating one person with HIV ($420,285) − keeping Americans healthy, HIV-free and productive. The moment of truth is here. As the administration and Congress consider their investment priorities for next year, we urge them to continue joining forces in the fight against AIDS in the United States and worldwide. Together, their investments over time have created this once-in-a-generation opportunity to end AIDS in America by 2030, as called for by President Trump. Together they can seize that opportunity by banking on prevention. Ryan would expect nothing less. Jeanne White-Ginder is the mother of Ryan White. World-renowned musician Elton John established the Elton John AIDS Foundation in 1992. This article originally appeared on USA TODAY: Elton John: US can end HIV, but Trump cuts threaten progress | Opinion
USA Today
16 hours ago
- USA Today
Texas politicians lead effort to study a psychedelic drug. What is ibogaine?
Ibogaine is illegal in the U.S., but growing evidence shows its promise treating the effects of traumatic brain injury and substance use disorder. A once obscure traditional psychedelic plant from Africa has made headlines recently as Texas pushes for more research and a prominent Republican wrote a vigorous endorsement of its possible use for the treatment of addiction and for veterans experiencing mental health issues. Ibogaine is illegal for use in the United States, but a growing body of evidence has shown its promise treating the effects of traumatic brain injury and substance use disorder. Earlier in June, Texas Gov. Greg Abbott signed legislation to allocate $50 million for clinical trials approved by the Food and Drug Administration to study ibogaine. Texas is set to lead research into the drug's benefits treating mental health issues and addiction as a potential medication. Former Energy Secretary Rick Perry, also a former Texas governor, wrote a June 27 Washington Post op-ed supporting ibogaine research and criticizing the legacy of the war on drugs, started by President Richard Nixon and touted by President Ronald Reagan. Perry said he has 'come to realize just how wrong that narrative was.' 'That fear-based messaging kept us from exploring treatments that could have saved countless lives,' Perry wrote. Perry and a growing number of conservatives have argued ibogaine could be one of those treatments. Here's what to know about the drug. What is ibogaine? Ibogaine derives from the root of the iboga plant native to western-central Africa. It's been used in ceremonial rituals for centuries. It has hallucinogenic properties. The United States outlawed ibogaine in 1967 along with other psychotropic drugs. The Controlled Substances Act of 1970 placed it as a schedule I hallucinogenic drug, along with marijuana. Ibogaine's classification prevented researchers from studying its effects. But unlike other schedule 1 drugs such as heroin, ibogaine has anti-addictive properties. There are risks since ibogaine can delay the body's normal electrical signals that control heart rhythm, which could lead to death. Other countries, such as Mexico, have allowed its use. American veterans and others have traveled to smaller, clandestine clinics for treatment to deal with depression, post-traumatic stress disorder and addiction. Many clinics are along the border and around cities such as Tijuana. Why is it in the news? At the state and federal level, there is growing interest in studying psychedelic drugs to treat veterans and others. Texas passed legislation earlier in June to study the drug with a public university alongside a company and hospital, Abbott's office said. Dr. Marty Makary, the FDA commissioner, has said expanding research on psychedelic drugs is a top priority for the Trump administration. In his op-ed, Perry cited the experiences of Morgan and Marcus Luttrell, twin combat veterans, who used ibogaine for recovery. Morgan Luttrell is now a Republican congressman from Texas who has advocated for ibogaine and other psychedelic drugs as treatment options. In January 2025, Perry and W. Bryan Hubbard, an advocate for ibogaine treatment, appeared on Joe Rogan's podcast to discuss ibogaine's benefits as a plant-based medicine. Hubbard led a Kentucky task force that sought to use opioid settlement funds to research ibogaine's effects to treat addiction, but the initiative failed to gain support in the state. Hubbard and Perry eventually launched the Texas Ibogaine Initiative, which helped spur the state funding. What has research shown? Research, such as a Stanford University study of 30 male combat veterans, has shown ibogaine's promise. Coupled with magnesium sulfate to address heart effects, ibogaine appeared to reduce symptoms of PTSD, anxiety and depression, and improve cognitive function from traumatic brain injury, according to the study, published in 2024 in the eminent journal Nature Medicine. Other studies have shown benefits treating addiction and depression. What do critics say? One issue with ibogaine is the ability to produce it, because it is derived from a rare plant and has mostly been used for ceremonial purposes. There is research to help innovate its safe production, but it could be difficult for the drug to be more widely available, as researchers at the University of California, Davis, Institute for Psychedelics and Neurotherapeutics have said. And while it's shown benefits with combat veterans, questions remain on its efficacy among randomized participants. With Texas' research, ibogaine could get closer to FDA approval for its use as a medication.
Yahoo
a day ago
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
